Reviews in Computational Chemistry Volume 18
Reviews in Computational Chemistry Volume 18
Reviews in Computational Chemistry Volume 18
- No tags were found...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Application of Scor<strong>in</strong>g Functions <strong>in</strong> Virtual Screen<strong>in</strong>g 69<br />
when docked <strong>in</strong>to the agonist structure, but more importantly, about half of<br />
the agonists are also among the 10% top ranked molecules <strong>in</strong> the database<br />
when docked <strong>in</strong>to the open, antagonist structure, where they have to compete<br />
with many structures form<strong>in</strong>g salt bridges.<br />
F<strong>in</strong>d<strong>in</strong>g Weak Inhibitors<br />
Seed<strong>in</strong>g experiments are often carried out with a handful of active compounds<br />
that have already been optimized for b<strong>in</strong>d<strong>in</strong>g to a given target. Enrichment<br />
factors achieved <strong>in</strong> this way are often mislead<strong>in</strong>g, because f<strong>in</strong>d<strong>in</strong>g potent<br />
<strong>in</strong>hibitors from among a number of random molecules is significantly easier<br />
than dist<strong>in</strong>guish<strong>in</strong>g weakly b<strong>in</strong>d<strong>in</strong>g <strong>in</strong>hibitors from nonb<strong>in</strong>ders. In practice,<br />
virtual screen<strong>in</strong>g will f<strong>in</strong>d, at best, <strong>in</strong>hibitors <strong>in</strong> the low micromolar range,<br />
simply because no chemical database will be large enough, diverse enough,<br />
and lucky enough to f<strong>in</strong>d optimized leads right away.<br />
The difficulties associated with weak b<strong>in</strong>ders are illustrated <strong>in</strong> Figure 7<br />
with thromb<strong>in</strong> as a target. The 7500 compound subset of the WDI mentioned<br />
above was docked <strong>in</strong>to the thromb<strong>in</strong> active site together with three sets of 100<br />
100<br />
90<br />
80<br />
70<br />
60<br />
50<br />
<strong>in</strong>hibitors with pK i 7-9<br />
<strong>in</strong>hibitors with pK i 5-7<br />
<strong>in</strong>hibitors with pK i 4-5<br />
40<br />
1 2 3 4 5 10 20 30 50 100<br />
Figure 7 Enrichment of three sets of 100 thromb<strong>in</strong> <strong>in</strong>hibitors that cover different ranges<br />
of activity. Less active compounds are more difficult to enrich.